nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—RALBP1—Vincristine—lymphatic system cancer	0.3	0.387	CbGbCtD
Sorafenib—ABCG2—Teniposide—lymphatic system cancer	0.059	0.0762	CbGbCtD
Sorafenib—ABCG2—Mitoxantrone—lymphatic system cancer	0.0413	0.0533	CbGbCtD
Sorafenib—CYP1A2—Carmustine—lymphatic system cancer	0.0362	0.0467	CbGbCtD
Sorafenib—CYP3A5—Teniposide—lymphatic system cancer	0.0327	0.0422	CbGbCtD
Sorafenib—ABCC4—Methotrexate—lymphatic system cancer	0.032	0.0413	CbGbCtD
Sorafenib—ABCC2—Vincristine—lymphatic system cancer	0.0314	0.0406	CbGbCtD
Sorafenib—ABCG2—Vincristine—lymphatic system cancer	0.0284	0.0367	CbGbCtD
Sorafenib—CYP2C19—Teniposide—lymphatic system cancer	0.0264	0.034	CbGbCtD
Sorafenib—CYP2C9—Teniposide—lymphatic system cancer	0.0219	0.0283	CbGbCtD
Sorafenib—CYP3A7—Vincristine—lymphatic system cancer	0.021	0.0271	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.021	0.0271	CbGbCtD
Sorafenib—ABCC2—Methotrexate—lymphatic system cancer	0.019	0.0246	CbGbCtD
Sorafenib—ABCG2—Methotrexate—lymphatic system cancer	0.0172	0.0222	CbGbCtD
Sorafenib—CYP3A5—Vincristine—lymphatic system cancer	0.0157	0.0203	CbGbCtD
Sorafenib—ABCB1—Mitoxantrone—lymphatic system cancer	0.0149	0.0192	CbGbCtD
Sorafenib—CYP3A4—Cytarabine—lymphatic system cancer	0.0129	0.0167	CbGbCtD
Sorafenib—CYP3A4—Teniposide—lymphatic system cancer	0.0128	0.0165	CbGbCtD
Sorafenib—ABCB1—Vincristine—lymphatic system cancer	0.0102	0.0132	CbGbCtD
Sorafenib—CYP3A4—Mitoxantrone—lymphatic system cancer	0.00892	0.0115	CbGbCtD
Sorafenib—ABCB1—Methotrexate—lymphatic system cancer	0.0062	0.008	CbGbCtD
Sorafenib—CYP3A4—Vincristine—lymphatic system cancer	0.00614	0.00792	CbGbCtD
Sorafenib—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.000447	0.00199	CcSEcCtD
Sorafenib—Pneumonia—Vincristine—lymphatic system cancer	0.000447	0.00199	CcSEcCtD
Sorafenib—Flushing—Bleomycin—lymphatic system cancer	0.000444	0.00197	CcSEcCtD
Sorafenib—Anorexia—Fludarabine—lymphatic system cancer	0.000442	0.00196	CcSEcCtD
Sorafenib—Weight decreased—Mitoxantrone—lymphatic system cancer	0.000439	0.00195	CcSEcCtD
Sorafenib—Proteinuria—Methotrexate—lymphatic system cancer	0.000439	0.00195	CcSEcCtD
Sorafenib—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.000438	0.00195	CcSEcCtD
Sorafenib—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.000436	0.00193	CcSEcCtD
Sorafenib—Myocardial infarction—Vincristine—lymphatic system cancer	0.000436	0.00193	CcSEcCtD
Sorafenib—Pneumonia—Mitoxantrone—lymphatic system cancer	0.000435	0.00193	CcSEcCtD
Sorafenib—Stomatitis—Vincristine—lymphatic system cancer	0.000433	0.00192	CcSEcCtD
Sorafenib—Protein urine present—Methotrexate—lymphatic system cancer	0.000433	0.00192	CcSEcCtD
Sorafenib—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000432	0.00192	CcSEcCtD
Sorafenib—Bone disorder—Methotrexate—lymphatic system cancer	0.000427	0.0019	CcSEcCtD
Sorafenib—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.000427	0.00189	CcSEcCtD
Sorafenib—Renal failure—Mitoxantrone—lymphatic system cancer	0.000426	0.00189	CcSEcCtD
Sorafenib—Nausea—Mechlorethamine—lymphatic system cancer	0.000425	0.00189	CcSEcCtD
Sorafenib—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.000424	0.00188	CcSEcCtD
Sorafenib—Alopecia—Bleomycin—lymphatic system cancer	0.000423	0.00188	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000423	0.00188	CcSEcCtD
Sorafenib—Stomatitis—Mitoxantrone—lymphatic system cancer	0.000422	0.00187	CcSEcCtD
Sorafenib—Jaundice—Mitoxantrone—lymphatic system cancer	0.000422	0.00187	CcSEcCtD
Sorafenib—Haemoglobin—Carmustine—lymphatic system cancer	0.00042	0.00187	CcSEcCtD
Sorafenib—Urticaria—Teniposide—lymphatic system cancer	0.000419	0.00186	CcSEcCtD
Sorafenib—Glossitis—Methotrexate—lymphatic system cancer	0.000418	0.00186	CcSEcCtD
Sorafenib—Haemorrhage—Carmustine—lymphatic system cancer	0.000418	0.00186	CcSEcCtD
Sorafenib—Abdominal pain—Teniposide—lymphatic system cancer	0.000417	0.00185	CcSEcCtD
Sorafenib—Body temperature increased—Teniposide—lymphatic system cancer	0.000417	0.00185	CcSEcCtD
Sorafenib—Erythema—Bleomycin—lymphatic system cancer	0.000417	0.00185	CcSEcCtD
Sorafenib—Dyspnoea—Fludarabine—lymphatic system cancer	0.000414	0.00184	CcSEcCtD
Sorafenib—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000411	0.00182	CcSEcCtD
Sorafenib—Dyspepsia—Fludarabine—lymphatic system cancer	0.000408	0.00181	CcSEcCtD
Sorafenib—Decreased appetite—Fludarabine—lymphatic system cancer	0.000403	0.00179	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000401	0.00178	CcSEcCtD
Sorafenib—Fatigue—Fludarabine—lymphatic system cancer	0.0004	0.00178	CcSEcCtD
Sorafenib—Pain—Fludarabine—lymphatic system cancer	0.000397	0.00176	CcSEcCtD
Sorafenib—Constipation—Fludarabine—lymphatic system cancer	0.000397	0.00176	CcSEcCtD
Sorafenib—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000394	0.00175	CcSEcCtD
Sorafenib—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000392	0.00174	CcSEcCtD
Sorafenib—Urethral disorder—Vincristine—lymphatic system cancer	0.000391	0.00174	CcSEcCtD
Sorafenib—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000391	0.00173	CcSEcCtD
Sorafenib—Hypersensitivity—Teniposide—lymphatic system cancer	0.000389	0.00173	CcSEcCtD
Sorafenib—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000389	0.00173	CcSEcCtD
Sorafenib—Flushing—Carmustine—lymphatic system cancer	0.000388	0.00172	CcSEcCtD
Sorafenib—Anaemia—Bleomycin—lymphatic system cancer	0.000385	0.00171	CcSEcCtD
Sorafenib—Asthenia—Teniposide—lymphatic system cancer	0.000379	0.00168	CcSEcCtD
Sorafenib—Pruritus—Teniposide—lymphatic system cancer	0.000374	0.00166	CcSEcCtD
Sorafenib—Arrhythmia—Carmustine—lymphatic system cancer	0.000373	0.00166	CcSEcCtD
Sorafenib—Leukopenia—Bleomycin—lymphatic system cancer	0.000373	0.00166	CcSEcCtD
Sorafenib—Cardiac disorder—Vincristine—lymphatic system cancer	0.00037	0.00164	CcSEcCtD
Sorafenib—Alopecia—Carmustine—lymphatic system cancer	0.000369	0.00164	CcSEcCtD
Sorafenib—Skin exfoliation—Methotrexate—lymphatic system cancer	0.000368	0.00163	CcSEcCtD
Sorafenib—Body temperature increased—Fludarabine—lymphatic system cancer	0.000367	0.00163	CcSEcCtD
Sorafenib—Mental disorder—Carmustine—lymphatic system cancer	0.000366	0.00163	CcSEcCtD
Sorafenib—Erythema—Carmustine—lymphatic system cancer	0.000364	0.00162	CcSEcCtD
Sorafenib—Malnutrition—Carmustine—lymphatic system cancer	0.000364	0.00162	CcSEcCtD
Sorafenib—Cough—Bleomycin—lymphatic system cancer	0.000364	0.00162	CcSEcCtD
Sorafenib—Angiopathy—Vincristine—lymphatic system cancer	0.000362	0.00161	CcSEcCtD
Sorafenib—Diarrhoea—Teniposide—lymphatic system cancer	0.000361	0.0016	CcSEcCtD
Sorafenib—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00036	0.0016	CcSEcCtD
Sorafenib—Myalgia—Bleomycin—lymphatic system cancer	0.000355	0.00158	CcSEcCtD
Sorafenib—Alopecia—Vincristine—lymphatic system cancer	0.000353	0.00157	CcSEcCtD
Sorafenib—Mental disorder—Vincristine—lymphatic system cancer	0.00035	0.00155	CcSEcCtD
Sorafenib—Neoplasm—Methotrexate—lymphatic system cancer	0.000349	0.00155	CcSEcCtD
Sorafenib—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000349	0.00155	CcSEcCtD
Sorafenib—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000347	0.00154	CcSEcCtD
Sorafenib—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000345	0.00153	CcSEcCtD
Sorafenib—Alopecia—Mitoxantrone—lymphatic system cancer	0.000343	0.00152	CcSEcCtD
Sorafenib—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000342	0.00152	CcSEcCtD
Sorafenib—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00034	0.00151	CcSEcCtD
Sorafenib—Erythema—Mitoxantrone—lymphatic system cancer	0.000338	0.0015	CcSEcCtD
Sorafenib—Infection—Bleomycin—lymphatic system cancer	0.000338	0.0015	CcSEcCtD
Sorafenib—Anaemia—Carmustine—lymphatic system cancer	0.000336	0.00149	CcSEcCtD
Sorafenib—Vomiting—Teniposide—lymphatic system cancer	0.000336	0.00149	CcSEcCtD
Sorafenib—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000333	0.00148	CcSEcCtD
Sorafenib—Asthenia—Fludarabine—lymphatic system cancer	0.000333	0.00148	CcSEcCtD
Sorafenib—Rash—Teniposide—lymphatic system cancer	0.000333	0.00148	CcSEcCtD
Sorafenib—Dermatitis—Teniposide—lymphatic system cancer	0.000333	0.00148	CcSEcCtD
Sorafenib—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000331	0.00147	CcSEcCtD
Sorafenib—Headache—Teniposide—lymphatic system cancer	0.000331	0.00147	CcSEcCtD
Sorafenib—Pruritus—Fludarabine—lymphatic system cancer	0.000328	0.00146	CcSEcCtD
Sorafenib—Leukopenia—Carmustine—lymphatic system cancer	0.000326	0.00145	CcSEcCtD
Sorafenib—Anorexia—Bleomycin—lymphatic system cancer	0.000324	0.00144	CcSEcCtD
Sorafenib—Anaemia—Vincristine—lymphatic system cancer	0.000321	0.00143	CcSEcCtD
Sorafenib—Diarrhoea—Fludarabine—lymphatic system cancer	0.000318	0.00141	CcSEcCtD
Sorafenib—Hypertension—Carmustine—lymphatic system cancer	0.000314	0.0014	CcSEcCtD
Sorafenib—Nausea—Teniposide—lymphatic system cancer	0.000314	0.00139	CcSEcCtD
Sorafenib—Anaemia—Mitoxantrone—lymphatic system cancer	0.000313	0.00139	CcSEcCtD
Sorafenib—Hepatic failure—Methotrexate—lymphatic system cancer	0.000311	0.00138	CcSEcCtD
Sorafenib—Leukopenia—Vincristine—lymphatic system cancer	0.000311	0.00138	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00031	0.00138	CcSEcCtD
Sorafenib—Myalgia—Carmustine—lymphatic system cancer	0.00031	0.00138	CcSEcCtD
Sorafenib—Dyspnoea—Bleomycin—lymphatic system cancer	0.000303	0.00135	CcSEcCtD
Sorafenib—Renal failure acute—Methotrexate—lymphatic system cancer	0.000303	0.00135	CcSEcCtD
Sorafenib—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000303	0.00134	CcSEcCtD
Sorafenib—Hypertension—Vincristine—lymphatic system cancer	0.0003	0.00133	CcSEcCtD
Sorafenib—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000297	0.00132	CcSEcCtD
Sorafenib—Decreased appetite—Bleomycin—lymphatic system cancer	0.000296	0.00131	CcSEcCtD
Sorafenib—Myalgia—Vincristine—lymphatic system cancer	0.000296	0.00131	CcSEcCtD
Sorafenib—Cough—Mitoxantrone—lymphatic system cancer	0.000295	0.00131	CcSEcCtD
Sorafenib—Infection—Carmustine—lymphatic system cancer	0.000295	0.00131	CcSEcCtD
Sorafenib—Vomiting—Fludarabine—lymphatic system cancer	0.000295	0.00131	CcSEcCtD
Sorafenib—Rash—Fludarabine—lymphatic system cancer	0.000293	0.0013	CcSEcCtD
Sorafenib—Dermatitis—Fludarabine—lymphatic system cancer	0.000292	0.0013	CcSEcCtD
Sorafenib—Hypertension—Mitoxantrone—lymphatic system cancer	0.000292	0.0013	CcSEcCtD
Sorafenib—Pain—Bleomycin—lymphatic system cancer	0.000291	0.00129	CcSEcCtD
Sorafenib—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000291	0.00129	CcSEcCtD
Sorafenib—Headache—Fludarabine—lymphatic system cancer	0.000291	0.00129	CcSEcCtD
Sorafenib—Myalgia—Mitoxantrone—lymphatic system cancer	0.000288	0.00128	CcSEcCtD
Sorafenib—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000288	0.00128	CcSEcCtD
Sorafenib—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000284	0.00126	CcSEcCtD
Sorafenib—Anorexia—Carmustine—lymphatic system cancer	0.000283	0.00126	CcSEcCtD
Sorafenib—Infection—Vincristine—lymphatic system cancer	0.000282	0.00125	CcSEcCtD
Sorafenib—Nervous system disorder—Vincristine—lymphatic system cancer	0.000278	0.00123	CcSEcCtD
Sorafenib—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000278	0.00123	CcSEcCtD
Sorafenib—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000276	0.00123	CcSEcCtD
Sorafenib—Nausea—Fludarabine—lymphatic system cancer	0.000276	0.00122	CcSEcCtD
Sorafenib—Infection—Mitoxantrone—lymphatic system cancer	0.000274	0.00122	CcSEcCtD
Sorafenib—Shock—Mitoxantrone—lymphatic system cancer	0.000272	0.00121	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000271	0.0012	CcSEcCtD
Sorafenib—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00027	0.0012	CcSEcCtD
Sorafenib—Urticaria—Bleomycin—lymphatic system cancer	0.00027	0.0012	CcSEcCtD
Sorafenib—Anorexia—Vincristine—lymphatic system cancer	0.00027	0.0012	CcSEcCtD
Sorafenib—Body temperature increased—Bleomycin—lymphatic system cancer	0.000269	0.00119	CcSEcCtD
Sorafenib—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000268	0.00119	CcSEcCtD
Sorafenib—Mood swings—Methotrexate—lymphatic system cancer	0.000265	0.00118	CcSEcCtD
Sorafenib—Dyspnoea—Carmustine—lymphatic system cancer	0.000265	0.00118	CcSEcCtD
Sorafenib—Anorexia—Mitoxantrone—lymphatic system cancer	0.000263	0.00117	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000258	0.00115	CcSEcCtD
Sorafenib—Decreased appetite—Carmustine—lymphatic system cancer	0.000258	0.00115	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000256	0.00114	CcSEcCtD
Sorafenib—Pain—Carmustine—lymphatic system cancer	0.000254	0.00113	CcSEcCtD
Sorafenib—Constipation—Carmustine—lymphatic system cancer	0.000254	0.00113	CcSEcCtD
Sorafenib—Breast disorder—Methotrexate—lymphatic system cancer	0.000253	0.00112	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000252	0.00112	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000252	0.00112	CcSEcCtD
Sorafenib—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000251	0.00111	CcSEcCtD
Sorafenib—Decreased appetite—Vincristine—lymphatic system cancer	0.000246	0.00109	CcSEcCtD
Sorafenib—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000246	0.00109	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000245	0.00109	CcSEcCtD
Sorafenib—Fatigue—Vincristine—lymphatic system cancer	0.000244	0.00109	CcSEcCtD
Sorafenib—Asthenia—Bleomycin—lymphatic system cancer	0.000244	0.00108	CcSEcCtD
Sorafenib—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000243	0.00108	CcSEcCtD
Sorafenib—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000243	0.00108	CcSEcCtD
Sorafenib—Pain—Vincristine—lymphatic system cancer	0.000242	0.00108	CcSEcCtD
Sorafenib—Constipation—Vincristine—lymphatic system cancer	0.000242	0.00108	CcSEcCtD
Sorafenib—Pruritus—Bleomycin—lymphatic system cancer	0.000241	0.00107	CcSEcCtD
Sorafenib—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00024	0.00107	CcSEcCtD
Sorafenib—Fatigue—Mitoxantrone—lymphatic system cancer	0.000238	0.00106	CcSEcCtD
Sorafenib—Pancreatitis—Methotrexate—lymphatic system cancer	0.000237	0.00105	CcSEcCtD
Sorafenib—Pain—Mitoxantrone—lymphatic system cancer	0.000236	0.00105	CcSEcCtD
Sorafenib—Constipation—Mitoxantrone—lymphatic system cancer	0.000236	0.00105	CcSEcCtD
Sorafenib—Abdominal pain—Carmustine—lymphatic system cancer	0.000235	0.00104	CcSEcCtD
Sorafenib—Body temperature increased—Carmustine—lymphatic system cancer	0.000235	0.00104	CcSEcCtD
Sorafenib—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000232	0.00103	CcSEcCtD
Sorafenib—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000232	0.00103	CcSEcCtD
Sorafenib—Neutropenia—Methotrexate—lymphatic system cancer	0.000226	0.001	CcSEcCtD
Sorafenib—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000226	0.001	CcSEcCtD
Sorafenib—Abdominal pain—Vincristine—lymphatic system cancer	0.000224	0.000995	CcSEcCtD
Sorafenib—Body temperature increased—Vincristine—lymphatic system cancer	0.000224	0.000995	CcSEcCtD
Sorafenib—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000223	0.000989	CcSEcCtD
Sorafenib—Urticaria—Mitoxantrone—lymphatic system cancer	0.000219	0.000974	CcSEcCtD
Sorafenib—Hypersensitivity—Carmustine—lymphatic system cancer	0.000219	0.000972	CcSEcCtD
Sorafenib—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000218	0.000969	CcSEcCtD
Sorafenib—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000218	0.000969	CcSEcCtD
Sorafenib—Pneumonia—Methotrexate—lymphatic system cancer	0.000217	0.000963	CcSEcCtD
Sorafenib—Vomiting—Bleomycin—lymphatic system cancer	0.000216	0.000961	CcSEcCtD
Sorafenib—Infestation NOS—Methotrexate—lymphatic system cancer	0.000216	0.000958	CcSEcCtD
Sorafenib—Infestation—Methotrexate—lymphatic system cancer	0.000216	0.000958	CcSEcCtD
Sorafenib—Rash—Bleomycin—lymphatic system cancer	0.000215	0.000953	CcSEcCtD
Sorafenib—Dermatitis—Bleomycin—lymphatic system cancer	0.000214	0.000952	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000214	0.00095	CcSEcCtD
Sorafenib—Asthenia—Carmustine—lymphatic system cancer	0.000213	0.000946	CcSEcCtD
Sorafenib—Renal failure—Methotrexate—lymphatic system cancer	0.000212	0.000941	CcSEcCtD
Sorafenib—Stomatitis—Methotrexate—lymphatic system cancer	0.00021	0.000934	CcSEcCtD
Sorafenib—Hypersensitivity—Vincristine—lymphatic system cancer	0.000209	0.000927	CcSEcCtD
Sorafenib—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000204	0.000906	CcSEcCtD
Sorafenib—Epistaxis—Methotrexate—lymphatic system cancer	0.000203	0.000903	CcSEcCtD
Sorafenib—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000203	0.000903	CcSEcCtD
Sorafenib—Asthenia—Vincristine—lymphatic system cancer	0.000203	0.000903	CcSEcCtD
Sorafenib—Diarrhoea—Carmustine—lymphatic system cancer	0.000203	0.000902	CcSEcCtD
Sorafenib—Nausea—Bleomycin—lymphatic system cancer	0.000202	0.000897	CcSEcCtD
Sorafenib—Asthenia—Mitoxantrone—lymphatic system cancer	0.000198	0.00088	CcSEcCtD
Sorafenib—Dizziness—Carmustine—lymphatic system cancer	0.000196	0.000872	CcSEcCtD
Sorafenib—Haemoglobin—Methotrexate—lymphatic system cancer	0.000195	0.000864	CcSEcCtD
Sorafenib—Diarrhoea—Vincristine—lymphatic system cancer	0.000194	0.000861	CcSEcCtD
Sorafenib—Haemorrhage—Methotrexate—lymphatic system cancer	0.000194	0.00086	CcSEcCtD
Sorafenib—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000191	0.000849	CcSEcCtD
Sorafenib—Urethral disorder—Methotrexate—lymphatic system cancer	0.00019	0.000843	CcSEcCtD
Sorafenib—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000189	0.000839	CcSEcCtD
Sorafenib—Vomiting—Carmustine—lymphatic system cancer	0.000189	0.000838	CcSEcCtD
Sorafenib—Dizziness—Vincristine—lymphatic system cancer	0.000187	0.000832	CcSEcCtD
Sorafenib—Rash—Carmustine—lymphatic system cancer	0.000187	0.000831	CcSEcCtD
Sorafenib—Dermatitis—Carmustine—lymphatic system cancer	0.000187	0.000831	CcSEcCtD
Sorafenib—Headache—Carmustine—lymphatic system cancer	0.000186	0.000826	CcSEcCtD
Sorafenib—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000183	0.000813	CcSEcCtD
Sorafenib—Tinnitus—Methotrexate—lymphatic system cancer	0.000181	0.000802	CcSEcCtD
Sorafenib—Vomiting—Vincristine—lymphatic system cancer	0.00018	0.0008	CcSEcCtD
Sorafenib—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00018	0.000798	CcSEcCtD
Sorafenib—Rash—Vincristine—lymphatic system cancer	0.000179	0.000794	CcSEcCtD
Sorafenib—Dermatitis—Vincristine—lymphatic system cancer	0.000179	0.000793	CcSEcCtD
Sorafenib—Headache—Vincristine—lymphatic system cancer	0.000178	0.000789	CcSEcCtD
Sorafenib—Nausea—Carmustine—lymphatic system cancer	0.000176	0.000783	CcSEcCtD
Sorafenib—Angiopathy—Methotrexate—lymphatic system cancer	0.000176	0.00078	CcSEcCtD
Sorafenib—Vomiting—Mitoxantrone—lymphatic system cancer	0.000176	0.000779	CcSEcCtD
Sorafenib—Immune system disorder—Methotrexate—lymphatic system cancer	0.000175	0.000777	CcSEcCtD
Sorafenib—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000175	0.000775	CcSEcCtD
Sorafenib—Rash—Mitoxantrone—lymphatic system cancer	0.000174	0.000773	CcSEcCtD
Sorafenib—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000174	0.000772	CcSEcCtD
Sorafenib—Headache—Mitoxantrone—lymphatic system cancer	0.000173	0.000768	CcSEcCtD
Sorafenib—Alopecia—Methotrexate—lymphatic system cancer	0.000171	0.00076	CcSEcCtD
Sorafenib—Mental disorder—Methotrexate—lymphatic system cancer	0.00017	0.000753	CcSEcCtD
Sorafenib—Malnutrition—Methotrexate—lymphatic system cancer	0.000169	0.000748	CcSEcCtD
Sorafenib—Erythema—Methotrexate—lymphatic system cancer	0.000169	0.000748	CcSEcCtD
Sorafenib—Nausea—Vincristine—lymphatic system cancer	0.000168	0.000748	CcSEcCtD
Sorafenib—Dysgeusia—Methotrexate—lymphatic system cancer	0.000165	0.000733	CcSEcCtD
Sorafenib—Nausea—Mitoxantrone—lymphatic system cancer	0.000164	0.000728	CcSEcCtD
Sorafenib—Anaemia—Methotrexate—lymphatic system cancer	0.000156	0.000692	CcSEcCtD
Sorafenib—Leukopenia—Methotrexate—lymphatic system cancer	0.000151	0.00067	CcSEcCtD
Sorafenib—Cough—Methotrexate—lymphatic system cancer	0.000147	0.000653	CcSEcCtD
Sorafenib—Arthralgia—Methotrexate—lymphatic system cancer	0.000143	0.000637	CcSEcCtD
Sorafenib—Myalgia—Methotrexate—lymphatic system cancer	0.000143	0.000637	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000143	0.000633	CcSEcCtD
Sorafenib—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000138	0.000611	CcSEcCtD
Sorafenib—Infection—Methotrexate—lymphatic system cancer	0.000137	0.000607	CcSEcCtD
Sorafenib—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000135	0.000599	CcSEcCtD
Sorafenib—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000135	0.000598	CcSEcCtD
Sorafenib—Skin disorder—Methotrexate—lymphatic system cancer	0.000134	0.000593	CcSEcCtD
Sorafenib—Anorexia—Methotrexate—lymphatic system cancer	0.000131	0.000582	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000125	0.000557	CcSEcCtD
Sorafenib—Dyspnoea—Methotrexate—lymphatic system cancer	0.000123	0.000545	CcSEcCtD
Sorafenib—Dyspepsia—Methotrexate—lymphatic system cancer	0.000121	0.000538	CcSEcCtD
Sorafenib—Decreased appetite—Methotrexate—lymphatic system cancer	0.00012	0.000531	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000119	0.000527	CcSEcCtD
Sorafenib—Fatigue—Methotrexate—lymphatic system cancer	0.000119	0.000527	CcSEcCtD
Sorafenib—Pain—Methotrexate—lymphatic system cancer	0.000118	0.000522	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000112	0.000499	CcSEcCtD
Sorafenib—Urticaria—Methotrexate—lymphatic system cancer	0.000109	0.000485	CcSEcCtD
Sorafenib—Abdominal pain—Methotrexate—lymphatic system cancer	0.000109	0.000483	CcSEcCtD
Sorafenib—Body temperature increased—Methotrexate—lymphatic system cancer	0.000109	0.000483	CcSEcCtD
Sorafenib—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000101	0.00045	CcSEcCtD
Sorafenib—Asthenia—Methotrexate—lymphatic system cancer	9.87e-05	0.000438	CcSEcCtD
Sorafenib—Pruritus—Methotrexate—lymphatic system cancer	9.73e-05	0.000432	CcSEcCtD
Sorafenib—Diarrhoea—Methotrexate—lymphatic system cancer	9.41e-05	0.000418	CcSEcCtD
Sorafenib—Dizziness—Methotrexate—lymphatic system cancer	9.1e-05	0.000404	CcSEcCtD
Sorafenib—Vomiting—Methotrexate—lymphatic system cancer	8.75e-05	0.000388	CcSEcCtD
Sorafenib—Rash—Methotrexate—lymphatic system cancer	8.67e-05	0.000385	CcSEcCtD
Sorafenib—Dermatitis—Methotrexate—lymphatic system cancer	8.67e-05	0.000385	CcSEcCtD
Sorafenib—Headache—Methotrexate—lymphatic system cancer	8.62e-05	0.000383	CcSEcCtD
Sorafenib—Nausea—Methotrexate—lymphatic system cancer	8.17e-05	0.000363	CcSEcCtD
